A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.

Abstract

Results demonstrate a remarkably high response rate in combining IFN-alpha and four chemotherapeutic agents. The apparent schedule-dependency of responses must be further explored in a controlled phase III study.